Skip to main content
Top
Published in: Journal of Neuroinflammation 1/2019

Open Access 01-12-2019 | Multiple Sclerosis | Research

Myelinoclastic diffuse sclerosis (Schilder’s disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures

Authors: S. Jarius, J. Haas, F. Paul, B. Wildemann

Published in: Journal of Neuroinflammation | Issue 1/2019

Login to get access

Abstract

Background

Myelinoclastic diffuse sclerosis (MDS; also termed Schilder’s disease) is a rare inflammatory demyelinating disorder of the central nervous system characterised by demyelination of vast areas of the white matter. It is unclear whether MDS is a variant of multiple sclerosis (MS) or a disease entity in its own right.

Objective

To compare the cerebrospinal fluid (CSF) features of MDS with those of MS.

Methods

Retrospective analysis of the CSF profile of all patients with MDS reported in the medical literature between 1960 and 2018.

Results

The most striking finding was a substantial lack of oligoclonal bands (OCBs) in MDS, which were absent in at least 77% (30/39) of all lumbar punctures (LP) in the total cohort and in 86% in the subgroup of patients with normal very long-chain fatty acid serum ratios (VLCFA). Almost all cases published in the past 15 years were negative for OCBs. These findings are in contrast to MS, in which OCBs are present in up to 98% of cases (p < 0.00001 when compared with reference works in MS; both in adult and in pediatric patients). CSF pleocytosis was absent in at least 79% (46/58) of all LP (p < 0.0001 vs. MS) and in 92% (24/26) of LPs in the VLCFA-tested subgroup. CSF total protein levels were elevated in 56% of all LPs (p < 0.0001 vs. MS) and in 63% of LPs in the VLCFA-tested subgroup and were often higher than in typical MS (> 100 mg/dL in 13/22; up to 220 mg/dL). EBV serum antibodies, which are present in virtually all patients with MS, and the so-called MRZ (measles/rubella/zoster) reaction, a highly specific marker of MS, were absent in all of the few patients tested. In addition, we discuss further differences between MS and MDS, taking into account also Schilder’s original comprehensive case description from 1912.

Conclusion

In the majority of patients diagnosed with MDS, CSF features differ significantly from those typically found in MS and are more similar to those previously reported in patients with myelin oligodendrocyte glycoprotein-immunoglobulin G (IgG)-positive encephalomyelitis, aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders or Baló’s concentric sclerosis. Our data suggest that MDS and MS are immunopathologically distinct entities in the majority of cases.
Literature
1.
go back to reference Schilder P. Zur Kenntnis der sogenannten diffusen Sklerose (über encephalitis periaxialis diffusa). Zeitschrift für die gesamte Neurologie und Psychiatrie. 1912;10:1–160.CrossRef Schilder P. Zur Kenntnis der sogenannten diffusen Sklerose (über encephalitis periaxialis diffusa). Zeitschrift für die gesamte Neurologie und Psychiatrie. 1912;10:1–160.CrossRef
2.
go back to reference Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82–90.CrossRef Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci. 2011;306:82–90.CrossRef
3.
go back to reference Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.CrossRef Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.CrossRef
4.
go back to reference Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264:453–66.CrossRef Jarius S, Eichhorn P, Franciotta D, Petereit HF, Akman-Demir G, Wick M, et al. The MRZ reaction as a highly specific marker of multiple sclerosis: re-evaluation and structured review of the literature. J Neurol. 2017;264:453–66.CrossRef
5.
go back to reference Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, Petereit HF, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2008;79:1134–6.CrossRef Jarius S, Franciotta D, Bergamaschi R, Rauer S, Wandinger KP, Petereit HF, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2008;79:1134–6.CrossRef
6.
go back to reference Jarius S, Franciotta D, Marchioni E, Hohlfeld R, Wildemann B, Voltz R. Intrathecal polyspecific immune response against neurotropic viruses discriminates between multiple sclerosis and acute demyelinating encephalomyelitis. J Neurol. 2006;253:486. Jarius S, Franciotta D, Marchioni E, Hohlfeld R, Wildemann B, Voltz R. Intrathecal polyspecific immune response against neurotropic viruses discriminates between multiple sclerosis and acute demyelinating encephalomyelitis. J Neurol. 2006;253:486.
7.
go back to reference Jarius S, Eichhorn P, Wildemann B, Wick M. Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands. Fluids Barriers CNS. 2012;9:14.CrossRef Jarius S, Eichhorn P, Wildemann B, Wick M. Usefulness of antibody index assessment in cerebrospinal fluid from patients negative for total-IgG oligoclonal bands. Fluids Barriers CNS. 2012;9:14.CrossRef
8.
go back to reference Jarius S, Konig FB, Metz I, Ruprecht K, Paul F, Bruck W, et al. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J Neuroinflammation. 2017;14:171.CrossRef Jarius S, Konig FB, Metz I, Ruprecht K, Paul F, Bruck W, et al. Pattern II and pattern III MS are entities distinct from pattern I MS: evidence from cerebrospinal fluid analysis. J Neuroinflammation. 2017;14:171.CrossRef
9.
go back to reference Jarius S, Eichhorn P, Jacobi C, Wildemann B, Wick M, Voltz R. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci. 2009;280:98–100.CrossRef Jarius S, Eichhorn P, Jacobi C, Wildemann B, Wick M, Voltz R. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci. 2009;280:98–100.CrossRef
10.
go back to reference Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.CrossRef Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13:280.CrossRef
11.
go back to reference Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.CrossRef Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation. 2016;13:279.CrossRef
12.
go back to reference Jarius S, Hoffmann L, Clover L, Vincent A, Voltz R. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci. 2008;268:74–7.CrossRef Jarius S, Hoffmann L, Clover L, Vincent A, Voltz R. CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci. 2008;268:74–7.CrossRef
13.
go back to reference Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56:1313–8.CrossRef Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B. Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology. 2001;56:1313–8.CrossRef
14.
go back to reference Schapira K, Park DC. Gamma globulin studies of multiple sclerosis and their application to the problem of diagnosis. J Neurol Neurosurg Psychiatry. 1961;24:121–4.CrossRef Schapira K, Park DC. Gamma globulin studies of multiple sclerosis and their application to the problem of diagnosis. J Neurol Neurosurg Psychiatry. 1961;24:121–4.CrossRef
15.
go back to reference Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12:769–74.CrossRef Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12:769–74.CrossRef
16.
go back to reference Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004;63:1966–7.CrossRef Pohl D, Rostasy K, Reiber H, Hanefeld F. CSF characteristics in early-onset multiple sclerosis. Neurology. 2004;63:1966–7.CrossRef
17.
go back to reference Reiber H. Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4:99–107.PubMed Reiber H. Cerebrospinal fluid--physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler. 1998;4:99–107.PubMed
18.
go back to reference Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998;4:111–7.CrossRef Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler. 1998;4:111–7.CrossRef
19.
go back to reference Becker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol. 2015;15:79.CrossRef Becker M, Latarche C, Roman E, Debouverie M, Malaplate-Armand C, Guillemin F. No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients. BMC Neurol. 2015;15:79.CrossRef
20.
go back to reference Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62:865–70.CrossRef Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62:865–70.CrossRef
21.
go back to reference Warren KG, Catz I, McPherson TA. CSF myelin basic protein levels in acute optic neuritis and multiple sclerosis. Can J Neurol Sci. 1983;10:235–8.CrossRef Warren KG, Catz I, McPherson TA. CSF myelin basic protein levels in acute optic neuritis and multiple sclerosis. Can J Neurol Sci. 1983;10:235–8.CrossRef
22.
go back to reference Wildemann B, Oschmann P, Reiber H. Laboratory diagnosis in neurology. Stuttgart, New York: Thieme; 2011. Wildemann B, Oschmann P, Reiber H. Laboratory diagnosis in neurology. Stuttgart, New York: Thieme; 2011.
23.
go back to reference Ashrafi MR, Tavasoli AR, Alizadeh H, Zare Noghabi J, Parvaneh N. Tumefactive multiple sclerosis variants: report of two cases of Schilder and Balo diseases. Iran J Child Neurol. 2017;11:69–77.PubMedPubMedCentral Ashrafi MR, Tavasoli AR, Alizadeh H, Zare Noghabi J, Parvaneh N. Tumefactive multiple sclerosis variants: report of two cases of Schilder and Balo diseases. Iran J Child Neurol. 2017;11:69–77.PubMedPubMedCentral
24.
go back to reference Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897–902.CrossRef Andersson M, Alvarez-Cermeno J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry. 1994;57:897–902.CrossRef
25.
go back to reference Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.CrossRef Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.CrossRef
26.
go back to reference Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol. 2004;56:308.CrossRef Lucchinetti CF, Bruck W, Lassmann H. Evidence for pathogenic heterogeneity in multiple sclerosis. Ann Neurol. 2004;56:308.CrossRef
27.
go back to reference Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17.CrossRef Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–17.CrossRef
28.
go back to reference Frohman EM, Kerr D. Is neuromyelitis optica distinct from multiple sclerosis? Something for "lumpers" and “splitters”. Arch Neurol. 2007;64:903–5.CrossRef Frohman EM, Kerr D. Is neuromyelitis optica distinct from multiple sclerosis? Something for "lumpers" and “splitters”. Arch Neurol. 2007;64:903–5.CrossRef
29.
go back to reference Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15:134. Jarius S, Paul F, Aktas O, Asgari N, Dale RC, de Seze J, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018;15:134.
30.
go back to reference Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81:298–309.CrossRef Flanagan EP, Hinson SR, Lennon VA, Fang B, Aksamit AJ, Morris PP, et al. Glial fibrillary acidic protein immunoglobulin G as biomarker of autoimmune astrocytopathy: analysis of 102 patients. Ann Neurol. 2017;81:298–309.CrossRef
31.
go back to reference Hahn S, Trendelenburg G, Scharf M, Denno Y, Brakopp S, Teegen B, et al. Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis. J Neuroinflammation. 2017;14:123.CrossRef Hahn S, Trendelenburg G, Scharf M, Denno Y, Brakopp S, Teegen B, et al. Identification of the flotillin-1/2 heterocomplex as a target of autoantibodies in bona fide multiple sclerosis. J Neuroinflammation. 2017;14:123.CrossRef
32.
go back to reference Titulaer MJ, Hoftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, et al. Overlapping demyelinating syndromes and anti-N-methyl-d-aspartate receptor encephalitis. Ann Neurol. 2014;75:411–28.CrossRef Titulaer MJ, Hoftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, et al. Overlapping demyelinating syndromes and anti-N-methyl-d-aspartate receptor encephalitis. Ann Neurol. 2014;75:411–28.CrossRef
33.
go back to reference Jarius S, Wurthwein C, Behrens JR, Wanner J, Haas J, Paul F, et al. Balo’s concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. J Neuroinflammation. 2018;15:22.CrossRef Jarius S, Wurthwein C, Behrens JR, Wanner J, Haas J, Paul F, et al. Balo’s concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures. J Neuroinflammation. 2018;15:22.CrossRef
34.
go back to reference Wallner-Blazek M, Rovira A, Fillipp M, Rocca MA, Miller DH, Schmierer K, et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol. 2013;260:2016–22.CrossRef Wallner-Blazek M, Rovira A, Fillipp M, Rocca MA, Miller DH, Schmierer K, et al. Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. J Neurol. 2013;260:2016–22.CrossRef
35.
go back to reference Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hummert MW, Trebst C, Pache F, Winkelmann A, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13:281.CrossRef Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hummert MW, Trebst C, Pache F, Winkelmann A, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation. 2016;13:281.CrossRef
36.
go back to reference Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.CrossRef Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13:282.CrossRef
37.
go back to reference Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica study group (NEMOS). J Neurol. 2013;261:1–16.CrossRef Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica study group (NEMOS). J Neurol. 2013;261:1–16.CrossRef
38.
go back to reference Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8 Jarius S, Wildemann B. The history of neuromyelitis optica. J Neuroinflammation. 2013;10:8
39.
go back to reference Gault F. In: Rey A, editor. De la neuromyélite optique aiguë. Thèse. Lyon: Faculté de Médecine et de Pharmacie; 1894. Gault F. In: Rey A, editor. De la neuromyélite optique aiguë. Thèse. Lyon: Faculté de Médecine et de Pharmacie; 1894.
40.
41.
go back to reference Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–64.CrossRef Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149–64.CrossRef
42.
go back to reference Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89.CrossRef Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89.CrossRef
43.
go back to reference Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6:383–92.CrossRef Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6:383–92.CrossRef
44.
go back to reference Baló J. Encephalitis periaxialis concentrica. Arch NeurPsych. 1928;19:242–6.CrossRef Baló J. Encephalitis periaxialis concentrica. Arch NeurPsych. 1928;19:242–6.CrossRef
45.
go back to reference Poser CM, Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg. 2004;106:159–71.CrossRef Poser CM, Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg. 2004;106:159–71.CrossRef
46.
go back to reference Schilder P. Zur Frage der encephalitis periaxialis diffusa. Zeitschrift für die gesamte Neurologie und Psychiatrie. 1913;15:359–76.CrossRef Schilder P. Zur Frage der encephalitis periaxialis diffusa. Zeitschrift für die gesamte Neurologie und Psychiatrie. 1913;15:359–76.CrossRef
47.
go back to reference Schilder P. Die encephalitis periaxialis diffusa. Zeitschrift für die gesamte Neurologie und Psychiatrie. 1924;71:327–56. Schilder P. Die encephalitis periaxialis diffusa. Zeitschrift für die gesamte Neurologie und Psychiatrie. 1924;71:327–56.
48.
go back to reference Poser CM, Van Bogaert L. Natural history and evolution of the concept of Schilder’ diffuse sclerosis. Acta Psychiatr Neurol Scand. 1956;31:285–331.CrossRef Poser CM, Van Bogaert L. Natural history and evolution of the concept of Schilder’ diffuse sclerosis. Acta Psychiatr Neurol Scand. 1956;31:285–331.CrossRef
49.
go back to reference Kurdi M, Ramsay D. Balo’s concentric lesions with concurrent features of Schilder’s disease in relapsing multiple sclerosis: neuropathological findings. Autops Case Rep. 2016;6:21–6.CrossRef Kurdi M, Ramsay D. Balo’s concentric lesions with concurrent features of Schilder’s disease in relapsing multiple sclerosis: neuropathological findings. Autops Case Rep. 2016;6:21–6.CrossRef
50.
go back to reference Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23:661–83.CrossRef Jarius S, Wildemann B. Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol. 2013;23:661–83.CrossRef
51.
go back to reference Jacobi C, Hahnel S, Martinez-Torres F, Rieger S, Juttler E, Heiland S, et al. Prospective combined brain and spinal cord MRI in clinically isolated syndromes and possible early multiple sclerosis: impact on dissemination in space and time. Eur J Neurol. 2008;15:1359–64.CrossRef Jacobi C, Hahnel S, Martinez-Torres F, Rieger S, Juttler E, Heiland S, et al. Prospective combined brain and spinal cord MRI in clinically isolated syndromes and possible early multiple sclerosis: impact on dissemination in space and time. Eur J Neurol. 2008;15:1359–64.CrossRef
52.
go back to reference Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol. 2009;68:489–502. Vercellino M, Masera S, Lorenzatti M, Condello C, Merola A, Mattioda A, et al. Demyelination, inflammation, and neurodegeneration in multiple sclerosis deep gray matter. J Neuropathol Exp Neurol. 2009;68:489–502.
53.
go back to reference Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol. 2005;64:1101–7.CrossRef Vercellino M, Plano F, Votta B, Mutani R, Giordana MT, Cavalla P. Grey matter pathology in multiple sclerosis. J Neuropathol Exp Neurol. 2005;64:1101–7.CrossRef
54.
go back to reference Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962;25:315–20.CrossRef Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1962;25:315–20.CrossRef
55.
go back to reference Lumsden CE. The neuropathology of multiple sclerosis. In: GWBE PJV, editor. Handbook of clinical neurology. Volume 9. Amsterdam: Elsevier; 1970. p. 217–309. Lumsden CE. The neuropathology of multiple sclerosis. In: GWBE PJV, editor. Handbook of clinical neurology. Volume 9. Amsterdam: Elsevier; 1970. p. 217–309.
56.
go back to reference Mesaros S, Rocca MA, Absinta M, Ghezzi A, Milani N, Moiola L, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology. 2008;70:1107–12.CrossRef Mesaros S, Rocca MA, Absinta M, Ghezzi A, Milani N, Moiola L, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology. 2008;70:1107–12.CrossRef
57.
go back to reference Granberg T, Fan Q, Treaba CA, Ouellette R, Herranz E, Mangeat G, et al. In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis. Brain. 2017;140:2912–26.CrossRef Granberg T, Fan Q, Treaba CA, Ouellette R, Herranz E, Mangeat G, et al. In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis. Brain. 2017;140:2912–26.CrossRef
58.
go back to reference Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188–97.CrossRef Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med. 2011;365:2188–97.CrossRef
59.
go back to reference Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140:617–27.CrossRef Jurynczyk M, Geraldes R, Probert F, Woodhall MR, Waters P, Tackley G, et al. Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis. Brain. 2017;140:617–27.CrossRef
60.
go back to reference Jurynczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88:132–6.CrossRef Jurynczyk M, Tackley G, Kong Y, Geraldes R, Matthews L, Woodhall M, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry. 2017;88:132–6.CrossRef
61.
go back to reference Baumann M, Grams A, Djurdjevic T, Wendel EM, Lechner C, Behring B, et al. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol. 2018;265:845–55.CrossRef Baumann M, Grams A, Djurdjevic T, Wendel EM, Lechner C, Behring B, et al. MRI of the first event in pediatric acquired demyelinating syndromes with antibodies to myelin oligodendrocyte glycoprotein. J Neurol. 2018;265:845–55.CrossRef
62.
go back to reference Eldridge R, Anayiotos CP, Schlesinger S, Cowen D, Bever C, Patronas N, et al. Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. N Engl J Med. 1984;311:948–53.CrossRef Eldridge R, Anayiotos CP, Schlesinger S, Cowen D, Bever C, Patronas N, et al. Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. N Engl J Med. 1984;311:948–53.CrossRef
63.
go back to reference van der Knaap MS, Valk J. Magnetic resonance of myelination and myelin disorders. 3rd edition edn. Heidelberg, Berlin, New York: Springer; 2005.CrossRef van der Knaap MS, Valk J. Magnetic resonance of myelination and myelin disorders. 3rd edition edn. Heidelberg, Berlin, New York: Springer; 2005.CrossRef
64.
go back to reference Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22:470–82.CrossRef Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22:470–82.CrossRef
65.
go back to reference Poser CM, Goutieres F, Carpentier MA, Aicardi J. Schilder’s myelinoclastic diffuse sclerosis. Pediatrics. 1986;77:107–12.PubMed Poser CM, Goutieres F, Carpentier MA, Aicardi J. Schilder’s myelinoclastic diffuse sclerosis. Pediatrics. 1986;77:107–12.PubMed
66.
go back to reference Afifi AK, Follett KA, Greenlee J, Scott WE, Moore SA. Optic neuritis: a novel presentation of Schilder’s disease. J Child Neurol. 2001;16:693–6.CrossRef Afifi AK, Follett KA, Greenlee J, Scott WE, Moore SA. Optic neuritis: a novel presentation of Schilder’s disease. J Child Neurol. 2001;16:693–6.CrossRef
67.
go back to reference Leuzzi V, Lyon G, Cilio MR, Pedespan JM, Fontan D, Chateil JF, et al. Childhood demyelinating diseases with a prolonged remitting course and their relation to Schilder’s disease: report of two cases. J Neurol Neurosurg Psychiatry. 1999;66:407–8.CrossRef Leuzzi V, Lyon G, Cilio MR, Pedespan JM, Fontan D, Chateil JF, et al. Childhood demyelinating diseases with a prolonged remitting course and their relation to Schilder’s disease: report of two cases. J Neurol Neurosurg Psychiatry. 1999;66:407–8.CrossRef
68.
go back to reference Kotil K, Kalayci M, Koseoglu T, Tugrul A. Myelinoclastic diffuse sclerosis (Schilder’s disease): report of a case and review of the literature. Br J Neurosurg. 2002;16:516–9.CrossRef Kotil K, Kalayci M, Koseoglu T, Tugrul A. Myelinoclastic diffuse sclerosis (Schilder’s disease): report of a case and review of the literature. Br J Neurosurg. 2002;16:516–9.CrossRef
69.
go back to reference Garell PC, Menezes AH, Baumbach G, Moore SA, Nelson G, Mathews K, et al. Presentation, management and follow-up of Schilder’s disease. Pediatr Neurosurg. 1998;29:86–91.CrossRef Garell PC, Menezes AH, Baumbach G, Moore SA, Nelson G, Mathews K, et al. Presentation, management and follow-up of Schilder’s disease. Pediatr Neurosurg. 1998;29:86–91.CrossRef
70.
go back to reference Nejat F, Eftekhar B. Decompressive aspiration in myelinoclastic diffuse sclerosis or Schilder disease. Case report. J Neurosurg. 2002;97:1447–9.CrossRef Nejat F, Eftekhar B. Decompressive aspiration in myelinoclastic diffuse sclerosis or Schilder disease. Case report. J Neurosurg. 2002;97:1447–9.CrossRef
71.
go back to reference Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175–89.CrossRef Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175–89.CrossRef
72.
go back to reference Johnson MD, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry. 1990;53:918–21.CrossRef Johnson MD, Lavin P, Whetsell WO Jr. Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry. 1990;53:918–21.CrossRef
73.
go back to reference Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61:288–99.CrossRef Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007;61:288–99.CrossRef
74.
go back to reference Ruprecht K, Wildemann B, Jarius S. Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature. J Neurol. 2018;265:239–52 Ruprecht K, Wildemann B, Jarius S. Low intrathecal antibody production despite high seroprevalence of Epstein-Barr virus in multiple sclerosis: a review of the literature. J Neurol. 2018;265:239–52
75.
go back to reference Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler. 2013;19:1209–12.CrossRef Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler. 2013;19:1209–12.CrossRef
76.
go back to reference von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, Oliveira EC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012;18:1038–41.CrossRef von Glehn F, Farias AS, de Oliveira AC, Damasceno A, Longhini AL, Oliveira EC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012;18:1038–41.CrossRef
77.
go back to reference Bacigaluppi S, Polonara G, Zavanone ML, Campanella R, Branca V, Gaini SM, et al. Schilder's disease: non-invasive diagnosis? :A case report and review. Neurol Sci. 2009;30:421–30. Bacigaluppi S, Polonara G, Zavanone ML, Campanella R, Branca V, Gaini SM, et al. Schilder's disease: non-invasive diagnosis? :A case report and review. Neurol Sci. 2009;30:421–30.
78.
go back to reference Tselis AC, Lisak RP. Other demyelinating diseases. In: Freedman MS, editor. Multiple sclerosis and demyelinating diseases. Philadelphia: Lippincott Williams & Williams; 2006. p. 335–49. Tselis AC, Lisak RP. Other demyelinating diseases. In: Freedman MS, editor. Multiple sclerosis and demyelinating diseases. Philadelphia: Lippincott Williams & Williams; 2006. p. 335–49.
79.
go back to reference Dunn-Pirio AM, Eckstein C. Recurrent Schilder’s disease. Mult Scler Relat Disord. 2018;26:8–10.CrossRef Dunn-Pirio AM, Eckstein C. Recurrent Schilder’s disease. Mult Scler Relat Disord. 2018;26:8–10.CrossRef
80.
go back to reference Miyamoto N, Kagohashi M, Nishioka K, Fujishima K, Kitada T, Tomita Y, et al. An autopsy case of Schilder’s variant of multiple sclerosis (Schilder’s disease). Eur Neurol. 2006;55:103–7.CrossRef Miyamoto N, Kagohashi M, Nishioka K, Fujishima K, Kitada T, Tomita Y, et al. An autopsy case of Schilder’s variant of multiple sclerosis (Schilder’s disease). Eur Neurol. 2006;55:103–7.CrossRef
81.
go back to reference Sastre-Garriga J, Rovira A, Rio J, Tintore M, Grive E, Montalban X. Clinically definite multiple sclerosis after radiological Schilder-like onset. J Neurol. 2003;250:871–3.CrossRef Sastre-Garriga J, Rovira A, Rio J, Tintore M, Grive E, Montalban X. Clinically definite multiple sclerosis after radiological Schilder-like onset. J Neurol. 2003;250:871–3.CrossRef
Metadata
Title
Myelinoclastic diffuse sclerosis (Schilder’s disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures
Authors
S. Jarius
J. Haas
F. Paul
B. Wildemann
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2019
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/s12974-019-1425-4

Other articles of this Issue 1/2019

Journal of Neuroinflammation 1/2019 Go to the issue